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Abstract
Background: Several human malignancies are associated with Epstein-Barr virus (EBV) and more than 95% of the adult
human population carries this virus lifelong. EBV efficiently infects human B cells and persists in this cellular compartment
latently. EBV-infected B cells become activated and growth transformed, express a characteristic set of viral latent genes,
and acquire the status of proliferating lymphoblastoid cell lines in vitro. Because EBV infects only primate cells, it has not
been possible to establish a model of infection in immunocompetent rodents. Such a model would be most desirable in
order to study EBV’s pathogenesis and latency in a suitable and amenable host.
Methodology/Principal Findings: We stably introduced recombinant EBV genomes into mouse embryonic stem cells and
induced their differentiation to B cells in vitro to develop the desired model. In vitro differentiated murine B cells maintained
the EBV genomes but expression of viral genes was restricted to the latent membrane proteins (LMPs). In contrast to human
B cells, EBV’s nuclear antigens (EBNAs) were not expressed detectably and growth transformed murine B cells did not arise
in vitro. Aberrant splicing and premature termination of EBNA mRNAs most likely prevented the expression of EBNA genes
required for B-cell transformation.
Conclusions/Significance: Our findings indicate that fundamental differences in gene regulation between mouse and man
might block the route towards a tractable murine model for EBV.
Citation: Zychlinska M, Herrmann H, Zimber-Strobl U, Hammerschmidt W (2008) Restricted Expression of Epstein-Barr Virus Latent Genes in Murine B Cells
Derived from Embryonic Stem Cells. PLoS ONE 3(4): e1996. doi:10.1371/journal.pone.0001996
Editor: Nina Papavasiliou, The Rockefeller University, United States of America
Received February 21, 2008; Accepted March 10, 2008; Published April 16, 2008
Copyright:  2008 Zychlinska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by institutional intramural grants, grants by the Deutsche Forschungsgemeinschaft (grants SPP 1230, SFB 455, SFB-Transregio
36), Krebshilfe grant 107277, and the National Institutes of Health grant CA70723-11.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hammerschmidt@helmholtz-muenchen.de
. These authors contributed equally to this work.
Introduction
Epstein-Barr virus (EBV) is a human herpesvirus, which has
been categorized as the first known human tumor virus [1]. This
virus is widespread and persists in all infected individuals as a
lifelong, usually asymptomatic and latent infection in the B-cell
compartment. Acute infection with EBV can cause infectious
mononucleosis, and its latent state can evolve to yield several B-cell
lymphomas, nasopharyngeal carcinoma and gastric cancer, and
other more sporadic malignancies [2,3]. Although EBV has been
studied extensively at the molecular level in vitro, conditions of virus
latency, virus-associated diseases and their pathogenesis are
difficult to study in the human population due to individual
variations in genetics, environment and behaviour.
EBV is highly species-specific in that it infects human and
certain primate cells, only. Much effort has gone into establishing a
suitable animal model for EBV but even the most advanced
models, i.e. humanized mice show considerable limits [4].
Experimental infections of mice with an EBV-related murine
herpesvirus termed MHV68 share certain features of EBV’s
pathogenesis and latency [5] but MHV68 does not encode
homologues of EBV latency-associated or transforming genes.
These EBV genes include the latent membrane proteins (LMP)1
and LMP2a as well as the EBV nuclear antigens (EBNA)2, and
EBNA1, among others. All of these latent gene products have
intrinsic activating characteristics [2,6–10] and thereby contribute
to growth transformation of human B cells, an accepted in vitro
model, which partially reflects EBV’s contributions to viral
oncogenesis.
A mouse model that embodies multiple features of EBV’s
infection would be most desirable to understand EBV’s contribu-
tion to viral latency and tumor development. In addition,
combining mouse genetics and viral mutants would open the
opportunity to unravel the relationship of the virus with its host at
the genetic and molecular level. EBV-susceptible transgenic mice
or primary murine cells, which carry a priori defined genetic
mutations in cellular genes presumably involved in EBV’s
pathogenesis, would be valuable tools and greatly advance our
understanding of the functions of cellular and viral gene products
and their critical interplay.
There are multiple viral and host restrictions, which uniquely
direct EBV’s susceptibility to humans including the human surface
receptor CD21 and HLA class II molecules, which are crucially
involved in virus adsorption and entry [11,12]. Recently, it has
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with both human genes became permissive to EBV and
maintained the viral genome stably in an extrachromosomal and
latent form [13]. Clearly, the infection rates were low and all
efforts to infect primary B cells derived from transgenic mice,
which express these two human surface molecules, have failed so
far [14] (R. Longnecker, personal communication). We, therefore,
followed a different route and introduced recombinant EBV
genomes into murine embryonic stem cells (mESCs) and induced
their differentiation to murine B cells in vitro in order to study EBV
and its functions in non-transformed mouse B cells.
Results
Establishment of mESC lines expressing EBNA1
In preliminary experiments (discussed below), we noticed that
mESCs did not survive selection when transfected with recombi-
nant EBV genomes encoding the G418 resistance gene neo.
Because nuclear retention and DNA replication of extrachromo-
somal EBV genomes depend on expression of the viral EBNA1
gene we considered that it might be expressed at insufficient levels
in mESCs. Therefore, we stably introduced EBNA1 into the mouse
rosa26 locus. This locus is known to assure stable expression of
inserted genes in all cell types [15]. Our genetic strategy is outlined
in Fig. 1A. EBNA1 was integrated into the first intron of the rosa26
gene in Bruce4 mESCs in two steps. First, the locus was targeted
with the linearized p3032 plasmid fragment carrying EBNA1 with
a preceding transcriptional stop cassette encompassing the neo
gene. The stop cassette was flanked by two loxP sites oriented in
the same direction. After successful transfection and selection, 400
G418-resistant single cell clones were obtained and analyzed for
correct homologous recombination by Southern blot hybridiza-
tion. Several correct clones were identified. In the second step, Cre
recombinase was transiently expressed in one of the mESC clones,
which led to the deletion of the stop cassette in 17 out of 20 clones
analyzed (Fig. 1A). Southern blot hybridizations confirmed this
genetic manipulation and concomitant removal of the neo gene
(Fig. 1B). Expression of EBNA1 was assessed by Western blots in
nine clones, four of which are shown in Fig 1C.
Introduction and maintenance of EBV genomes in
EBNA1-expressing mESCs
One EBNA1
+ mESC clone, Bruce4 EBNA1 C1 (Fig. 1B, C),
was electroporated with three different recombinant genomic EBV
plasmids. Plasmid p3053 contains the complete EBV genome of
the prototypic EBV strain B95.8, which was cloned onto a mini-F-
plasmid in E.coli. Like its parental version p2089 [16], p3053
encodes gfp but in addition carries the G418 resistance gene neo
located in the prokaryotic backbone (Fig 2A). This maxi-EBV
plasmid is fully competent to give rise to progeny virus when
propagated in appropriate cells or can directly mediate growth
transformation of human B cells upon DNA transfection [16,17].
p3298 is a variant of p3053 that is incapable of expressing EBV’s
latent genes other than LMP2B and EBERs and was used as a
negative control (not shown). The mini-EBV plasmid p3314 is
approximately half the size of a wild-type EBV genome, lacks the
majority of EBV’s lytic genes required for de novo virus synthesis
(Fig. 2B) but carries all known latent EBV genes. This
Figure 1. Targeting of EBNA1 into the rosa26 locus. (A) Molecular
cloning strategy. A loxP flanked transcriptional stop cassette (stop) and
the selectable maker gene for G418 resistance (neo
r) precede the EBNA1
gene in the rosa26 intron bracketed by exon 1 (e1) and exon 2 (e2)
(top). After Cre-mediated deletion EBNA1 is transcribed from the
ubiquitously expressed rosa26 locus in Bruce4 EBNA1 cells (bottom). (B)
Southern blot analysis of several Bruce4 EBNA1 cell lines after Cre-
mediated deletion of the stop cassette. The radioactive probe, depicted
in (A), distinguishes between the initial targeted situation (8.7 kb) and
deletion of the stop cassette (4.8 kb). (C) Expression of EBNA1 in
different Bruce4 EBNA1 cell lines as confirmed by immunodetection
(arrowhead). EBNA1-positive 293 cells serve as positive control,
negative controls are mouse embryonic fibroblasts and parental mESCs
(Bruce4).
doi:10.1371/journal.pone.0001996.g001
EBV in Murine Cells
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human B cells as efficiently as wild-type EBV [17,18].
The recombinant maxi- and mini-EBV plasmids were sepa-
rately introduced into the mESC clone Bruce4 EBNA1 C1 and
selected with G418. Cells derived from several independent
experiments were phenotypically and genotypically analyzed. GFP
expression could be detected in mESCs electroporated with p3053
or p3298 (Fig. 3A) and the extrachromosomal status of the
recombinant EBV genomes in all cell lines was confirmed by
Gardella gel analysis (Fig. 3B). With this technique, intact large
extrachromosomal EBV plasmids can be separated from genomic
DNA and detected by Southern blot hybridization. Clearly, this
technique does not exclude the possibility of integrated EBV DNA
also present in the selected mESCs. In summary, the Bruce4
EBNA1 C1 mESC clone readily supported the maintenance of all
different EBV plasmids, whereas the parental EBNA1-negative
Bruce4 cells did not (data not shown).
Selected viral and cellular genes expressed in EBV
+
mESCs
We asked whether EBV promoters and cellular genes
characteristic of embryonic stem cell genes were transcribed in
mESCs cells stably carrying the recombinant EBV genomes.
Using conventional and semi-quantitative real-time PCR we
investigated the expression of three key viral genes: EBNA2, LMP1,
and LMP2A, all involved in EBV-induced B-cell growth
transformation, and two cellular genes, Oct4 and Nanog, required
for pluripotency and primarily expressed in undifferentiated ESCs
[19]. Upon reverse transcription of total cellular RNA, cDNAs
were amplified with specific primers designed to span at least one
intron, in order to discriminate between amplification of cDNA or
the genomic DNA template (Table S1). In all mESC lines carrying
maxi-EBV p3053 or mini-EBV p3314 genomes, Oct4, Nanog, and
both LMP genes were expressed but EBNA2 transcripts were not
detected (Fig. 3C; Table 1). The LMP1 gene product could not be
detected directly in immunoblots indicating that its expression
level was very low (data not shown). Alternatively, failure to detect
LMP1 protein could be due to aberrant mRNA splicing of its
transcript (see below). As expected, the control maxi-EBV p3298
did not show transcription of any of these latent viral genes (Fig. 3C
and data not shown).
EBNA2 and other members of the EBNA gene family (EBNA-LP,
EBNA3A, -B, -C, and EBNA1) are expressed from multiply spliced
transcripts, which originate from the Cp and/or Wp promoters
(Fig. 2). By RT-PCR, we analyzed the activities of the Cp and Wp
promoters with appropriate primer pairs (Fig. 4A, B and Table.
S1). The positive control with cDNA derived from the B95.8 cell
line gave the characteristic ladder of orderly spliced exon repeats
(Fig. 4A, B). Cp- and Wp-specific cDNAs could be readily detected
in EBV-transduced mESCs but the amplified cDNAs revealed
only two of the expected PCR products (312 bp and 510 bp with
Cp-specific primers; 110 bp and 308 bp with Wp-specific primers;
Fig. 4A, B) in contrast to B95.8. Moreover, the PCR products
indicative of longer, multiply spliced adducts were absent in EBV-
positive mESCs while additional, smaller and prominent bands
appeared which were not present in B95.8 cells (Fig. 4A, B). The
unexpected bands were isolated from the gels and directly
sequenced. The three aberrant bands amplified with the Wp-
specific primer pair were 192, 390, and 588 bp in size and
contained intron sequences as schematically shown in Fig. 4C;
similar to the unexpected Cp-specific fragments (Fig. 4B and data
not shown). It thus appears that alternative RNA splicing in
mESCs resulted in retained introns in common EBNA transcripts.
In addition, premature termination of aberrantly spliced mRNAs
was evident. It is likely that both processes contributed to the
failure of these cells to express EBNA2 and other members of the
EBNA gene family, including EBNA1.
In vitro B cell differentiation of mECSs
Our final goal was to study EBV’s phenotype in mouse B cells in
vitro. We also expected that viral genes like EBNA2, which were not
expressed in mESCs (Fig. 3C), might be expressed upon differ-
entiation to cells of the B-cell lineage. mESCs can be differentiated
Figure 2. Recombinant EBV genomes. The maxi-EBV construct
p3053 encompasses the prototypic EBV genome of the B95.8 strain [16],
while the mini-EBV constructs p3314 lacks most lytic genes but encodes
all latent viral genes [17]. Both plasmids can be selectively propagated
in bacteria (F-factor replicon) under chloramphenicol selection (cam
r in
p3314, not marked in p3053) and in eukaryotic cells under G418
selection (neo
r). p3053 also encodes gfp. Only latent viral genes are
depicted, blue stands for EBNA genes and orange for LMP genes.
Selected promoters are shown with arrowheads. ‘W’ stands for BamHI-
W-repeats; oriP stands for the plasmid origin of replication, oriLyt is the
active replication origin during virus synthesis. Terminal repeats (TR) are
indispensable for encapsidation of virion DNA.
doi:10.1371/journal.pone.0001996.g002
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protocols to improve the rate of B cell differentiation (Fig. 5A) to
obtain sufficient numbers of B cells from the originally described
EB5 mESC line, EBNA1-expressing Bruce4 mESCs and deriva-
tives carrying the recombinant maxi- and mini-EBV genomes.
Drug selection for the maintenance of the recombinant EBV
genomes could not be applied during the differentiation process
because OP9 feeder cells are sensitive to G418. The recombinant
EBV genomes were stably maintained in mESCs for several weeks
without selection (data not shown) and under conditions of mESC
differentiation (below).
The EB5 mESC line, Bruce4 EBNA1 C1 cells and several
derivatives carrying the recombinant EBV genomes p3053 or
p3314 were cultivated according to the protocol shown in Fig. 5A
with similar results. The efficiencies of B cell differentiation with
EB5 and Bruce4 EBNA1 mESCs were comparable. Both
immature (IgM
+) and mature (IgM
+/IgD
+) B cells arose by about
three weeks of differentiation. Representative examples are shown
in Fig. 5B. Generally, in the lymphocyte gate .80% of viable cells
were CD19
+/B220
+ B cells; the majority of this B cell population
was IgM
2 (pro/pre B cells) and minor populations of up to 8%
and 3% expressed IgM and IgD respectively.
On day 21 of culture, the differentiated mESCs were separated
into two subpopulations, IgM surface-positive and -negative cells
by appropriate antibodies and selection with magnetic beads.
From the IgM
+ and IgM
2 cell populations cellular DNA and
RNA were isolated, cDNAs were prepared and expression of the
three viral latent genes EBNA2, LMP1 and LMP2A was analyzed
by real-time PCR. The results are summarized in Table 2. EBV
DNA was readily detectable in both populations, demonstrating
that the mini- and maxi-EBV genomes were maintained during B
cell differentiation for weeks. Parallel to our findings in mESCs,
LMP1 and LMP2A were clearly expressed in the IgM
+ fraction and
EBNA2 was undetectable. IgM
2 cell populations consisted of 20–
30% B cells (IgM
2 pro/pre B cells; data not shown). In IgM
2
cells, LMP2A- and EBNA2-specific transcripts were absent and
LMP1-specific PCR products were inconsistently detectable
(Table 2). The numbers of cells, which we could generate in vitro
limited the amount of RNA preventing a detailed analysis of the
activities of the Cp and Wp promoters.
We interpret the lack of EBNA2 expression to mean that similar
to EBV-positive mESCs, abberant mRNA splicing and/or
premature termination blocked the expression of this gene and
presumably that of other members of the EBNA family.
Figure 3. mini- and maxi-EBVs in Bruce4 EBNA1 mESCs. (A) GFP
expression of the stably introduced maxi-EBV constructs p3053 and
p3298 in Bruce4 EBNA1 cells. (B) Gardella gel hybridizations reveal the
extrachromosomal status of the recombinant EBV genomes. Raji cells,
which contain about 50 EBV genomes per cell served as a positive
control. In each single lane, 5610
6 Bruce4 EBNA1 cells carrying different
recombinant EBVs as indicated were loaded. (C) Detection of cellular
transcripts (actin, Oct4, Nanog) and viral transcripts (EBNA2, LMP1,
LMP2) by RT-PCR amplification. Selected Bruce4 EBNA1 clones stably
transduced with the indicated recombinant EBV constructs are shown.
doi:10.1371/journal.pone.0001996.g003
Table 1. Results of RT-PCR analysis of mESC lines stably
transduced with two recombinant EBV genomes.
EBV DNA GAPDH EBNA2 LMP1 LMP2A
Bruce4 EBNA1 3314 A4 ++ – ++
Bruce4 EBNA1 3314 E3 ++ – ++
Bruce4 EBNA1 3314 D5 ++ – ++
Bruce4 EBNA1 3053 P1 ++ – ++
Bruce4 EBNA1 3053 P2 ++ – ++
Bruce4 EBNA1 3053 P3 ++ – ++
Bruce4 EBNA1 3053 P4 ++ – ++
B95.8 ++ + + +
(+) indicates detection of cDNA of a given transcript, minus (–) its absence.
B95.8 cells serve as positive control for EBV’s latent genes. The gene encoding
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), is an ubiquitously
expressed housekeeping gene, which serve as another positive control for
correct cDNA synthesis and PCR amplification. EBV (+) indicates detection of
genomic EBV DNA. Primers used are listed in Table S1.
doi:10.1371/journal.pone.0001996.t001
EBV in Murine Cells
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yield lymphoblastoid cell lines; such lines readily originate from
EBV-infected human B cells of any stage of differentiation
including immature and even precursor B cells lacking rearranged
immunoglobulin genes [2,22–24]. The expression pattern of
EBV’s latent genes in mESCs or IgM
+ B cells was reminiscent
of the latency II program observed in human tumors and in vitro
EBV-infected B cell lymphoma cell lines [25,26]. In summary,
EBV-transformed murine B cells did not arise in this in vitro model,
presumably due to their failure to express the latent EBNA genes.
Discussion
EBV has been known for more than 40 years but a small-animal
model, which would allow the study of different aspects of EBV’s
biology and its contribution to malignancies is still lacking. A
mouse susceptible to infection with EBV would constitute such a
model, but murine cells are refractory to infection by EBV. Several
attempts to overcome this obstacle by e.g. expressing human
CD21 and/or human HLA class II molecules in primary murine B
cells in vitro or in transgenic mice have met with limited success
[13,14] (R. Longnecker, personal communication). It is unclear
why these approaches did not yield the desired mouse model but it
is clear that properties in addition to the successful early steps of
infection are required for such a model.
More is known about the maintenance (i.e. nuclear retention
and DNA replication) of the EBV genome in murine cells. Upon
transduction of recombinant EBV DNA, the viral genome is stably
and extrachromosomally maintained in murine B cell lines
engineered to co-express human CD21 and HLA class II [13]
indicating that mouse B cells have the ability to support
extrachromosomal EBV genomes similar to human cells [27].
EBNA1 is the indispensable viral factor, which mediates nuclear
retention and replication of the EBV genome; but EBNA1 also
transactivates other EBNAs [8,28,29]. We had found that mESCs
could be easily transfected with genomic EBV DNA but their
selection did not lead to stable cell lines retaining EBV. We
suspected EBNA1 to be needed and engineered an EBNA1-
positive mESC line (Fig. 1). Upon DNA transfection, all
recombinant EBV genomes conferred G418 resistance (Fig. 3)
and, once established, were even maintained for up to four weeks
without selection (Table 2). All EBV-transfected EBNA1-mESCs
were microscopically normal (Fig. 3A) and expressed Nanog and
Oct4 (Fig. 3C) indicative of their undifferentiated, pluripotent state
[19]. Thus, introducing a fully transformation-competent EBV
genome into embryonic stem cells does not reveal a profound
phenotype.
It was evident that mESCs neither supported expression of
EBNA1 as indicated by our initial observations nor EBNA2 as
revealed by PCR analysis (Fig. 3C, Table 1). EBNA1 can be
expressed from three different promoters: Qp, Wp, or Cp; other
members of the EBNA family (EBNA3A,- 3B,- 3C, EBNA-LP) are
transcribed from Wp or Cp (Fig. 2). We did not analyze Qp’s
activity but Wp and Cp were clearly transcriptionally active
(Fig. 4). The 5’-ends of viral EBNA transcripts, which originate
from Cp or Wp consist of an array of small exons, which are
multiply spliced. The typical ladder of PCR products reflects the
sequential assembly of W1 and W2 exon pairs, which stem from
each copy of the so-called BamHI-W-repeats (Fig. 2) as
demonstrated in B95.8 cells (Fig. 4). Although p3053 and p3314
differ in the number of their BamHI-W-repeats, identical patterns
of PCR products were detected (Fig. 4A, B). PCR products
obtained with Wp-specific primer pairs (Fig. 4B) revealed only two
out of five bands, which comigrated with those from B95.8 cells.
Figure 4. RT-PCR analysis of the Cp and Wp promoters
indicated incorrect splicing and premature termination of viral
EBNA transcripts in mESCs. RT-PCR analyses of EBNA-specific
transcripts with primer pairs, which selectively amplify Cp or Wp
originating transcripts. The expected patterns of multiply spliced exon
combinations are schematically depicted. (A) C1/W2 primer pairs
amplify transcripts, which originate from Cp. (B) W0W1’B/W2 primer
pairs detect transcripts from Wp. The agarose gels show the RT-PCR
patterns of different EBV-transduced Bruce4 EBNA1 clones together
with the positive controls derived from B95.8 cells. (C) Off-size PCR
products were isolated from gels as shown in B and directly sequenced.
Their composition is schematically shown.
doi:10.1371/journal.pone.0001996.g004
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transcripts with one and two BamHI-W-repeats, respectively
(Fig. 4B), the remaining bands were composed of incompletely
spliced products schematically depicted in Fig. 4C. No correctly
spliced transcripts exceeding 400 bp could be detected (Fig. 4A, B)
even in mESCs stably transduced with p3054, which carries about
ten copies of the BamHI-W-repeats (Fig. 2). It thus appeared that
intron retention within the 59 end of EBNA transcripts and
premature termination of Cp and Wp transcripts abrogated
expression of EBNAs in mESCs. Clearly, intron retention can
downregulate expression of the encoding gene [30] or inhibit its
translation [31].
Figure 5. In vitro differentiation of EBV-transduced mESC lines. (A) Schematic protocol of the different steps, which lead to in vitro
differentiated murine B cells. Cobblestone indicates the appearance of cell areas in which hematopoietic precursors develop. (B) Flow cytometry
analysis of selected cell cultures gated on lymphocytes of EB5 mESCs, the Bruce4 EBNA1 clone C1 and two derivatives transduced with the
recombinant EBV genomes p3053 and p3314 as indicated. Numbers indicate the percentage of B cells (B220
+/CD19
+), IgM
+ B cells and IgM
+/IgD
+ B
cells within the lymphocyte gate. Cells were analyzed between day 20 and day 23 of the differentiation protocol.
doi:10.1371/journal.pone.0001996.g005
EBV in Murine Cells
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cells as compared to hematopoietic cells but not necessarily
conserved between orthologous genes in mouse and man [32].
Therefore, we hoped that expression of EBNA genes might resume
upon differentiation of mESCs to murine B cells. B cells
presumably also support epigenetic changes of latent EBV
genomes [33], similar to epigenetic modifications during differen-
tiation of ESCs into somatic cells [34].
We improved the protocol for differentiation of mESCs into B
cells, so that in some experiments even mature IgM
+/IgD
+ Bc e l l s
could be detected (Fig. 5B). Because the differentiated B cells
maintained the transduced EBV genomes (Table 2), we hoped that
upon B-cell differentiation murine lymphoblastoid cell lines might
arise, as is the case with human B cells infected with EBV. However,
no such cell line could be obtained. The results summarized in
Table 2 clearly indicated that IgM
+ cells expressed only LMP1 and
LMP2A but not EBNA2 similar to in vitro infected murine B cell
lymphoma cell lines [13]. We concluded that this unexpected failure
prevented the outgrowth of EBV-transformed lymphoblastoid cell
lines. Unfortunately, we did not obtain sufficient RNA for a more
comprehensive analysis of transcripts originating from Cp or Wp
but, given our findings with mESCs, we hypothesize that aberrant
RNA splicing and/or premature termination of transcripts was
responsibleforthisoutcome.Itwouldbeinterestingtoknowwhether
such splicing alterations arise as a result of altered transcription due
to epigenetic marking of the viral genome in murine cells, e.g. DNA
methylation or heterochromatin formation in and around the
BamHI-W-repeat region.
To our knowledge no report describes in vitro differentiation of
human embryonic stem cells (hESCs) to B cells, thus a positive
control in parallel to our experiments with mESCs was not
feasible. EBV-derived plasmids can be maintained in hESCs [35]
and according to published reports, EBV is capable of transform-
ing human B cells of all stages of differentiation including
progenitor, pro- and pre-B cells [22–24]. These reports suggest
that our experimental approach could theoretically be extended to
hESCs to give rise to classical lymphoblastoid cell lines. One of our
initial goals was to study EBV in recipient B cells with different
genetic backgrounds. Because hESCs can be genetically altered,
our strategy could be adopted to hESCs assuming that they will
give rise to any cell of the B cell lineage.
In conclusion, fundamental differences in gene regulation and
presumably processing of mRNAs between mouse and man
appears to block the route towards a tractable murine model for
EBV. It is not obvious to us how this unexpected problem could be
solved except by ectopic expression of EBV’s EBNA genes in
mouse B cells.
Materials and Methods
Cell lines and culture condition
Bruce4 mouse embryonic stem cells (mESC) are derived from
the C57/BL6 mouse strain and were cultured in DMEM and
10%FCS with 1.2 mM sodium pyruvate, 1.2 mM glutamine and
0.12 mM b-mercaptoethanol complemented with 1.2x non-
essential amino acids and 1800 u/ml ESGRO (Chemicon).
Murine embryonic fibroblasts (mEF) isolated from transgenic
mouse embryos carrying the gene for neomycin phospho-
transferase (neo) were used as feeder cells and seeded on dishes
covered with 2% gelatine in PBS. Prior to plating of mESCs, mEF
were mitotically inactivated with mitomycin C (10 mg/ml) for 2–
4 h. OP9, a stromal cell line derived from newborn op/op mice
carrying an inactivating mutation in the M-CFS gene [20] was
cultured in a-MEM, 20%FCS, 0.1 mM b-mercaptoethanol.
B95.8, a lymphoblastoid monkey cell line, which releases the
prototypic EBV B95.8 virus [36] and Raji, an EBV-positive
Burkitt Lymphoma cell line [37], were maintained in RPMI1640
medium with 10%FCS, 100 mg/ml streptomycin, 100units/ml
penicillin G, 1.2 mM sodium pyruvate, and 10 mM HEPES.
Primers used in quantitative real-time PCR (qRT) and RT-
PCR
PCR detection of viral DNA was performed with the
oligonucleotide primer pair 2190 B2 and 2190 F3. cDNAs specific
for viral transcripts encoding the EBNA2, LMP1, LMP2A genes,
and the complex patterns of transcripts originating from the Cp
and Wp promoters, which drive expression of the different EBNA
genes, were assessed with appropriate primer pairs listed in Table
S1. PCR detection of mouse GAPDH or actin cDNAs served as a
positive control.
DNA extraction, restriction enzyme cleavage, and
Southern blot analysis
Isolation of cellular DNA, and Southern blot hybridisations
were performed according to standard protocols. DNA probes
were labeled with [a
32P] dCTP with High Prime probe staining kit
(Roche). After probe denaturation (95uC for 5 min), the
membranes were hybridized in Church buffer at 65uC overnight.
The blots were washed in 0.2xSSC/1%SDS buffer at 60–65uC.
Autoradiography was carried out at –80uC with intensifying
screens (Biomax MS).
Protein isolation and Western blot analysis
Cells were lysed in Laemmli buffer (2.5% SDS, 20 % glycerol,
0.12 M Tris pH 6.8) supplemented with protease inhibitor Com-
plete Mini Tablets (Roche). Protein concentrations were determined
with the DC Protein Assay (Bio-Rad). Protein samples were
electrophoretically separated on SDS-PAGE gels, transferred to
Hybond-C membranes (Amersham Pharmacia) and incubated with
a primary antibody for EBNA1 (1H4) and a secondary horse radish-
conjugated anti-rat goat antibody (Dianova). Chemiluminescent
signals were detected with ECL reagent (Amersham Pharmacia).
Plasmid DNA isolation, DNA transfection, and an
establishment of mESC lines
Plasmids up to 30 kb were propagated in the DH5a E.coli strain
and extracted with the Jet Star DNA Isolation Kit (Genomed).
Table 2. Results of RT-PCR analysis of in vitro differentiated
murine B cells transduced with two recombinant EBV
genomes.
EBV DNA GAPDH EBNA2 LMP1 LMP2A
Bruce4 EBNA1 3314 A4 IgM
+ ++ – ++
Bruce4 EBNA1 3314 A4 IgM
2 ++ – + –
Bruce4 EBNA1 3053 P1 IgM
+ ++ – ++
Bruce4 EBNA1 3053 P1 IgM
2 ++ –– –
B95.8 ++ + + +
(+) indicates detection of cDNA of a given transcript, minus (2) its absence.
B95.8 cells serve as positive control for EBV’s latent genes. The gene encoding
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), is an ubiquitously
expressed housekeeping gene, which serve as another positive control for
correct cDNA synthesis and PCR amplification. EBV (+) indicates detection of
genomic EBV DNA. Primers used are listed in Table S1.
doi:10.1371/journal.pone.0001996.t002
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a modified alkaline lysis protocol. Plasmid DNA was purified on
cesium chloride/ethidium bromide gradients, precipitated with
isopropanol and dissolved in TE. 1610
7 mESCs were electropo-
rated (2.3 kV, 500 mF) in 700 ml RPMI 1640 with 25 mg plasmid
DNA. After 48 hours, the cells were selected with G418 (0.4 mg/
ml) for up to 11 days. Single colonies were picked in PBS and
trypsinized prior to plating on 96-well plates.
Gardella gel assays
5610
6 cells in 50 ml of 15% Ficoll were loaded per slot on a
0.8% agarose gel in TBE (89 mM Tris-HCl, 89 mM Borate,
2 mM EDTA). The gel slice above the slots consisted of agarose
containing 2% SDS and 1 mg/ml proteinase K to allow lysis of
the cells and release of intact extrachromosomal DNA. Gels were
run at 4uC at 20 V for 3 h and overnight at 120 V. DNAs were
detected by Southern blot analysis.
RNA isolation, reverse-transcription and PCR analysis
RNA was isolated with the RNeasy Midi Kit (Qiagen). 2–5 mg
of total cellular RNA was reverse-transcribed with the cDNA
Synthesis System (Invitrogen). Oligo-(dT)20 primers were dena-
tured for 5 min at 65uC and mixed with 10x RT-buffer (25 mM
MgCl2, 0.1 M DTT, 40units/ml RNase) and Superscript
TMIII-
Reverse Transcriptase. The reaction was carried at 50uC for
50 min and terminated by heating at 85uC for 5 min. Samples
were incubated with 2units/ml RNaseH at 37uC for 20 min. For
real-time PCR, cDNA obtained from 2.5–5 mg RNA was diluted
1:10 and analyzed in the LightCycler machine (Roche). 10 mlo f
the reaction consisted of 1 ml cDNA, 0.8 ml MgCl2 (25 mM),
50 pmol of each primer, 1 ml polymerase mix and water. The
PCR reactions were carried out for up to 55 cycles. For RT-PCR,
the following conditions were applied. Each sample contained 2 ml
cDNA, 1x KCl buffer, 0.2 mM dNTPs mix, 50 pmol of each
primer, 3 units Taq-DNA-Polymerase (Fermentas), 0.2 ml DMSO
and 1–1.5 mM MgCl2 for up to 35 cycles.
In vitro B cell differentiation
The published differentiation protocol [21] was modified as
follows: On day 0, 1610
4 mESCs were plated in one well of a six-
well cluster plate in differentiation medium (a-MEM, 10% FCS,
0.1 mM b-mercaptoethanol) on OP9 feeder cells. The medium
was exchanged on day 3. On day 5 loosely adherent cells were
transferred to a new well with OP9 feeder cells to remove
undifferentiated mESCs and highly proliferative mesenchymal
cells. Medium supplemented with Flt3L (20 ng/ml) was added for
three additional days. Non-adherent small cells were transferred to
two wells of a six-well cluster plate and cultivated on OP9 feeder
cells until up to day 21 but in the absence of Flt3L. When B220
+/
CD19
+/IgM
+ cells were identified in the supernatant, the cell
culture was kept until day 28 of the experiment to allow B cell
maturation to IgD
+ cells.
FACS analysis and MACS cell sorting
Prior to cytometry cell samples were washed with PBS/2%FCS
and incubated with suitable antibodies conjugated to fluorescent
dyes (anti-B220-RA3-6B2, 1:200, mouse, PerCp; anti-B220-RA3-
6B2, 1:250, mouse, APC; anti-CD19-1D3, 1:400, mouse, PE; anti-
IgM-II/41, 1:200, mouse, APC; anti-IgD-11-26c.2a, 1:800,
mouse, FITC; all by Pharmingen) diluted in PBS/2%FCS. Dead
cells were stained with propidium iodide. When possible, 5610
4
lymphocytes (defined by the lymphocyte gate) were analyzed per
sample. IgM
+ cells were separated by magnetic cell sorting
(Miltenyi Biotec) on day 21. All cells in the flow-through were
considered as IgM
2 population.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0001996.s001 (0.04 MB
DOC)
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